Today, the fight against cancer is at its peak. Many research scientists are coming up with alternative ways to cure cancer. Many of them have come to agree that the methods that were used in the past are not as effective as there are presented to be. As a result, scientists like Clay Siegal are conducting research to come up with more effective methods that can be employed to permanently treat this condition.
Clay Segal is the president, founder, CEO and chairman of the board of Seattle genetics. Seattle genetics is a company that focuses on developing and selling monoclonal antibody based therapies. Unlike traditional methods, these therapies are designed to harness the targeting abilities of monoclonal antibodies to deliver the drugs directly to targeted cancer cells. This makes it easy to kill the cancerous cells thus ending their harmful effect to the body. The therapy is designed to spare the non-targeted cells, this eliminates the effects of traditional medical therapies.
As the CEO of the company, CEO Clay Siegall has inspired innovation among his team. Focusing on the mission of the company which is to come up with new methods of cancer treatment, Clay is determined to lead his team to better innovations and research methods. His experience as an oncology researcher for over 20 years has been a great asset to the company. Under his leadership, Seattle Genetics has been able to develop a therapy referred to as the ADCETRIS (brentuximab vedotin) which was approved as fit for consumption in hospitals by the U.S. Food and Drug Administration (FDA) in 2011.
His success in his research and his experience as the CEO of a leading company in cancer research, has also made him an authority in the field of oncology. He tries to advocate for the circulation of the findings made in research. In his official wordpress page, MR. Segal tackles different issues in oncology, his main aim in doing this is to increase knowledge of the findings made in cancer research. In his posts he tries express his views concerning the progress made in oncology.